Stellate Therapeutics

Risk score

57
Large logo of Stellate Therapeutics

Headquarters

Flag of United States of AmericaUnited States of America

Stellate Therapeutics is an early-stage startup company focused on developing pioneering microbiome-derived small molecules for the treatment of neurodegenerative conditions. Our drug portfolio relies on the microbiome, with particular emphasis on the gut-brain connection. Through the extensive co-evolution between humans and their gut bacteria, intricate metabolic interactions have emerged, and Stellate has identified a distinct set of metabolites produced by the microbiome that play a key role in sustaining health. Our initial medication aims to address Parkinson’s disease.